Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis

Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis

Abstract Background B‐lineage acute lymphoblastic leukemia (B‐ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial burden experienced by patients and society requires evaluation. Aims This study aim...

Full description

Bibliographic Details
Main Authors: Alex Hoover, Paige Reimche, Dave Watson, Lynn Tanner, Laura Gilchrist, Mike Finch, Yoav H. Messinger, Lucie M. Turcotte
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Reports
Subjects:
ALL
CAR‐T
cost
pediatric
Online Access:https://doi.org/10.1002/cnr2.1980

Similar Items

Similar Items